Stock Traders Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw some unusual options trading on Tuesday. Investors purchased 13,196 call options on the company. This represents an increase of approximately 374% compared to the average volume of 2,782 call options.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the period. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.18% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, January 10th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.00.

Reviva Pharmaceuticals Stock Performance

Shares of Reviva Pharmaceuticals stock traded up $0.19 during midday trading on Tuesday, hitting $1.96. The company had a trading volume of 1,687,465 shares, compared to its average volume of 2,809,732. The company has a 50 day moving average of $1.66 and a 200 day moving average of $1.32. The stock has a market capitalization of $65.61 million, a P/E ratio of -1.80 and a beta of -0.12. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.83.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.